SciELO - Scientific Electronic Library Online

 
vol.37 número5Prevalence of Torque teno virus in healthy donors of Paraná State, southern BrazilMyeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Revista Brasileira de Hematologia e Hemoterapia

versão impressa ISSN 1516-8484versão On-line ISSN 1806-0870

Resumo

FURTADO, Vanessa Fiorini et al. Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase. Rev. Bras. Hematol. Hemoter. [online]. 2015, vol.37, n.5, pp.341-347. ISSN 1516-8484.  https://doi.org/10.1016/j.bjhh.2015.07.004.

BACKGROUND:

Published criteria defining the accelerated phase in chronic myeloid leukemia are heterogeneous and little is known about predictors of poor outcome.

METHODS:

This is a retrospective study of 139 subjects in the accelerated phase of chronic myeloid leukemia treated with imatinib at a single center in Brazil. The objective was to identify risk factors for survival, major cytogenetic response and progression to blast phase in this population. The factors analyzed were: blasts 10-29%, basophils ≥ 20%, platelets > 1 × 106/µL or <1 × 105/µL and white blood cells > 1 × 105/µL in the peripheral blood, as well as clonal evolution, splenomegaly, hemoglobin < 10 g/dL, time between diagnosis of chronic myeloid leukemia and imatinib treatment, and hematologic toxicity.

RESULTS:

Risk factors for poor survival in multivariate analysis were Grades 3-4 hematologic toxicity (p-value = 0.001), blasts 10-29% (p-value = 0.023), and hemoglobin < 10 g/dL (p-value = 0.04). Risk factors for not achieving major cytogenetic response were blasts 10-29% (p-value = 0.007), hemoglobin < 10 g/dL (p-value = 0.001), and previous use of interferon (p-value = 0.032). Risk factors for progression to the blast phase were hemoglobin < 10 g/dL (p-value = 0.005), basophils ≥ 20% (p-value = 0.023), and time from diagnosis of chronic myeloid leukemia to imatinib treatment > 12 months (p-value = 0.030).

CONCLUSION:

These data indicate that patients with the above risk factors have a worse prognosis. This information can guide the therapy to be used.

Palavras-chave : Chronic myeloid leukemia; Accelerated phase; Imatinib; Prognostic factor; Mortality.

        · texto em Inglês     · Inglês ( pdf )